Latest Breaking News On - Marco timmers - Page 1 : comparemela.com

Roche vet James Sabry departs—Chutes & Ladders

Roche vet James Sabry departs—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Kevin gormanKyle ganoNeurocrine biosciencesIdeaya biosciencesVered bisker leibJames ahlersAndrew bellingerPhil nicksonTroy listerDaniel simonRoche genentechPaula oconnorEric trachtenbergPasit phiasivongsaThomas schineckerMarco timmers

New HER2 Drug for Breast Cancer Stalled by FDA

The FDA said it needs more data the new antibody-drug conjugate (ADC) trastuzumab duocarmazine for use in advanced or metastatic breast cancer.

United kingdomUnited statesMarco timmersDrug administrationEuropean unionMetastatic breast carcinomaAntineoplastic drugNti cancer agentsBiologic therapyHumanized monoclonal antibodyBreast cancerAlignant breast neoplasmHer2 positive breast cancerHer2 breast cancerAlignant neoplasiaAntibody drug conjugates adcs

FDA Issues Complete Response Letter for Trastuzumab Duocarmazine in Advanced HER2+ Breast Cancer

The FDA has issued a complete response letter to the biologics license application for vic-trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic breast cancer.

United kingdomSaura manichMarco timmersEuropean unionDrug administrationFda has issueda complete response letterBiologics license application for vic trastuzumab duocarmazineHer2 positive unresectableOcally advanced or metastatic breast cancerPhase 3 tulip trial

Preclinical Characterization of Anti-SIRPα mAb BYON4228 Published in Journal for ImmunoTherapy of Cancer

/PRNewswire/ Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that the Journal for.

Marco timmersYvonne massarWim dokterPrnewswire byondisPublic eyes healthcare communicationsSociety for immunotherapy of cancerCorporate communicationsByondi leadEnter phasei study thisSignal regulatory proteinChief scientific officer wim dokterChief executive officer marco timmersGood manufacturing practicePublic eyes healthcare

EMA validates application for Byondis trastuzumab duocarmazine

EMA validates application for Byondis trastuzumab duocarmazine
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

United kingdomMarco timmersEuropean medicines agencyMarketing authorisation applicationEuropean economic area